Journal
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 25, Issue 8, Pages 1621-1629Publisher
AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.2013121300
Keywords
-
Categories
Funding
- National Institutes of Health Grants [R01-HL085757, R01-DK093770, P30-DK079310, K24-DK090203]
- National Institutes of Health [U01-DK082185]
Ask authors/readers for more resources
Interest in developing and using novel markers of kidney injury is increasing. To maintain scientific rigour in these endeavors, a comprehensive understanding of statistical methodology is required to rigorously assess the incremental value of novel biomarkers in existing clinical risk prediction models. Such knowledge is especially relevant, because no single statistical method is sufficient to evaluate a novel biomarker. In this review, we highlight the strengths and limitations of various traditional and novel statistical methods used in the literature for biomarker studies and use biomarkers of AKI as examples to show limitations of some popular statistical methods.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available